Company

Actavis

As of the edition of 20 October 2026, Actavis runs 62 drugs, 44 of them marketed; it is on route A at 10 targets and on route B at 8 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

Actavis was renamed in 2015.

The records place 13 company names in this family.

  • Furiex Pharmaceuticals, Inc: acquired in 2014; successor Forest Laboratories
  • Actavis Inc.: renamed in 2015
  • Watson Pharmaceuticals: renamed in 2017
  • Forest Laboratories: acquired

Drugs by status

StatusCount
Marketed44
Active1
Went quiet7
Stopped10
Total62

Marketed drugs and when their US protection ends

DrugUS protectionRoute B rows
Docetaxel anhydrousnone listed0
Metforminnone listed4
Pemetrexednone listed7
AzacitidineEnds 2029 (exclusivity)4
EscitalopramEnded 2026 (exclusivity)4
Epinephrinenone listed23
Hydrochlorothiazidenone listed4
EstradiolEnds 2032 (patent)6
Metronidazolenone listed0
Testosteronenone listed4
Furosemidenone listed2
Memantinenone listed5
Citalopramnone listed3
Triptorelinnone listed0
Allopurinolnone listed0
Ursodiolnone listed1
Indomethacinnone listed3
Nebivololnone listed1
Oxybutyninnone listed3
Levoleucovorinnone listed0
CariprazineEnds 2029 (patent)4
Lovastatinnone listed1
LinaclotideEnds 2029 (exclusivity)3
AvibactamEnds 2033 (exclusivity)0
Milnaciprannone listed3

A route B row is one company at one target. 19 more marketed drugs are not listed here.

Where it needs a new molecule

Route A at 10 targets, route B at 8 targets.

Three of its 18 rows, by target and route
TargetRoute
ADRB1 Beta-1 adrenergic receptorRoute B
DPP4 Dipeptidyl peptidase 4Route A
PLG Plasminogen [Cleaved into: PlasminRoute A

All 18 rows on route A or B

In the product

18 company-target rows on route A or B; 15 are not shown here, and no score is.

Where its trials are

  • Mental health: 28 trials led
  • Digestive system: 16 trials led
  • Heart and blood vessels: 15 trials led